Assertio Holdings, Inc. (ASRT)

NASDAQ: ASRT · IEX Real-Time Price · USD
2.95
+0.04 (1.37%)
Nov 25, 2022 1:00 PM EDT - Market closed
1.37%
Market Cap 141.50M
Revenue (ttm) 139.21M
Net Income (ttm) 25.68M
Shares Out 48.18M
EPS (ttm) 0.53
PE Ratio 5.57
Forward PE 7.51
Dividend n/a
Ex-Dividend Date n/a
Volume 304,014
Open 2.94
Previous Close 2.91
Day's Range 2.9 - 3
52-Week Range 1.26 - 4.44
Beta 1.67
Analysts Buy
Price Target 6.12 (+107.5%)
Earnings Date Nov 8, 2022

About ASRT

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, a... [Read more]

Industry Pharmaceuticals
IPO Date Nov 5, 1997
Employees 19
Stock Exchange NASDAQ
Ticker Symbol ASRT
Full Company Profile

Financial Performance

In 2021, ASRT's revenue was $111.01 million, an increase of 4.46% compared to the previous year's $106.28 million. Losses were -$1.28 million, -95.45% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 107.46% from the latest price.

Price Target
$6.12
(107.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Other symbols: ZTS
2 days ago - Zacks Investment Research

Should Value Investors Buy Assertio (ASRT) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

3 days ago - Zacks Investment Research

Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Assertio Reports Third Quarter 2022 Financial Results

Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36% Increases Guidance for Net Product Sales and Adjusted EBITDA Debt Refinancing Extends Maturity, Reduces Cost and Inc...

2 weeks ago - GlobeNewsWire

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Other symbols: ZTS
2 weeks ago - Zacks Investment Research

Are Investors Undervaluing Assertio (ASRT) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

3 weeks ago - Zacks Investment Research

Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients...

4 weeks ago - GlobeNewsWire

Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.

Trailing 12 Month Revenues of Sympazan Were $9.5 Million Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance

4 weeks ago - GlobeNewsWire

The 7 Best Penny Stocks to Buy Now

As stocks remain in a bear market, even the best penny stocks continue to trade at depressed price levels. With macro uncertainties like inflation, rising interest rates, and a possible recession still ...

Other symbols: FRBKGSATGTEJOBNNDMREI
4 weeks ago - InvestorPlace

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

ASRT or UTHR: Which Is the Better Value Stock Right Now?

ASRT vs. UTHR: Which Stock Is the Better Value Option?

Other symbols: UTHR
1 month ago - Zacks Investment Research

Assertio to Participate in October 2022 Investor Conferences

LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients...

1 month ago - GlobeNewsWire

Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock

Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

1 month ago - Zacks Investment Research

ASRT vs. STVN: Which Stock Is the Better Value Option?

ASRT vs. STVN: Which Stock Is the Better Value Option?

Other symbols: STVN
1 month ago - Zacks Investment Research

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market

These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in ...

Other symbols: MMPMORIOTSN
1 month ago - InvestorPlace

Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?

Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

1 month ago - Zacks Investment Research

Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround

Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

2 months ago - Zacks Investment Research

Assertio (ASRT) Flat As Market Sinks: What You Should Know

Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.

2 months ago - Zacks Investment Research

ASRT vs. STVN: Which Stock Should Value Investors Buy Now?

ASRT vs. STVN: Which Stock Is the Better Value Option?

Other symbols: STVN
2 months ago - Zacks Investment Research

Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

2 months ago - Zacks Investment Research

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Assertio to Participate in the 2022 Lake Street BIG6 Conference

LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patient...

2 months ago - GlobeNewsWire

Assertio (ASRT) Upgraded to Buy: Here's Why

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

ASRT or CORT: Which Is the Better Value Stock Right Now?

ASRT vs. CORT: Which Stock Is the Better Value Option?

Other symbols: CORT
3 months ago - Zacks Investment Research